Tardive Dyskinesia

Karla Soares-Weiser; Hubert H. Fernandez

doi:10.1055/s-2007-971169

Seminars in Neurology, Table of Contents

Semin Neurol 2007; 27(2): 159-169
DOI: 10.1055/s-2007-971169

Tardive Dyskinesia

Karla Soares-Weiser¹ , Hubert H. Fernandez²

¹Enhance Reviews, Kfar-Saba, Israel
²Department of Neurology, University of Florida/McKnight Brain Institute, Gainesville, Florida

Abstract

ABSTRACT

This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references. We also contacted the authors of each included trial. All randomized clinical trials that compared different types of active interventions with placebo or no intervention in patients with neuroleptic-induced TD were included in our data. Two reviewers independently applied the selection criteria to all identified references, appraised the methodological quality of each trial, and extracted the relevant data. Relative risks and 95% confidence intervals were estimated using the fixed effect model. More than 500 randomized trials evaluating over 90 different interventions to treat TD were identified. From those, 45 trials were included in the current reviews. None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention.

KEYWORDS

Tardive dyskinesia - antipsychotics - neuroleptic-induced movement disorders

Full Text

References

REFERENCES

1 Schonecker M. Ein eigentumliches Syndrom im oralem Bereich bei Megaphenapplikation. Nervenarzt. 1957; 28 550-553
2 Sigwald J, Bouttier D, Raymondeaud C, Piot C. Quatre cas de dyskinesie facio-bucco-linguo-masticatrice a l'evolution prolongee secondaire a un traitement par less neuroleptiques. Rev Neurol (Paris). 1959; 100 751-755
3 Faurbye A, Rasch P, Peterson P, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand. 1964; 40 10-27
4 Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995; 18 197-214
5 Yassa R, Lai S. Respiratory irregularity and tardive dyskinesia. Acta Psychiatr Scand. 1986; 73 506-510
6 Fenn D S, Moussaoui D, Hoffman W F et al.. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl). 1996; 123 206-210
7 Fenton W S, Blyler C R, Wyatt R J, McGlashan T H. Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry. 1997; 171 265-268
8 Kane J M, Woerner M, Borenstein M et al.. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986; 22 254-258
9 Barnes T R, Kidger T, Gore S M. Tardive dyskinesia: a 3-year follow-up study. Psychol Med. 1983; 13 71-81
10 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988; 8(suppl) 52S-56S
11 Gardos G, Casey D, Cole J et al.. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994; 151 836-841
12 Halliday J, Farrington S, MacDonald S, MacEwan T, Sharley V, McCreadie R. Nithsdale Schizophrenia Survey 23: movement disorders-20 year review. Br J Psychiatry. 2002; 181 422-427
13 Kane J M, Smith J M. Tardive dyskinesia: prevalence and risk factors. Arch Gen Psychiatry. 1982; 39 473-481
14 Muscettola G, Pampallona S, Barbato G, Casiello M, Bolini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993; 87 29-36
15 Jeste D V, Caliguiri M P. Tardive dyskinesia (review). Schizophr Bull. 1993; 19 303-315
16 Jeste D V. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000; 61(suppl 4) 27-32
17 Wegner J T, Kane J M. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiatry. 1982; 139 368-369
18 Klawans H L, Tanner C M, Barr A. The reversibility of “permanent” tardive dyskinesia. Clin Neuropharmacol. 1984; 7 153-159
19 Casey D E, Povlsen U J, Meidahl B et al.. Neuroleptic-induced tardive dyskinesia and parkinsonism: change during several years of continuing treatment. Psychopharmacol Bull. 1986; 22 250-253
20 Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985; 34 211-219
21 Gardos G, Cole J O, Haskell D et al.. The natural history of tardive dyskinesia. J Clin Psychopharmacol. 1988; 8(suppl) 31S-37S
22 Fernandez H H, Krupp B, Friedman J H. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001; 56 805-807
23 Hitri A, Weiner W, Borison R et al.. Dopamine binding following prolonged haloperidol pretreatment. Ann Neurol. 1978; 3 134-140
24 Klawans H L, Tanner C M, Goetz C G. Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol. 1988; 49 185-197
25 Steen V M, Lovlie R, MacEwan T, McCreadie R G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997; 2 139-145
26 Tsai G, Goff D, Chang R, Flood J, Baer L, Coyle J. Markers of glutamitergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998; 155 1207-1213
27 Lohr J B. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry. 1991; 48 1097-1106
28 Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006; (3) CD000459
29 El-Sayeh H G, Lyra da Silva J P, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1) CD000458
30 Soares K, Rathbone J, Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2004; (4) CD000203
31 Soares K V, McGrath J J. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000; (2) CD000204
32 Soares K V, McGrath J J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001; (4) CD000209
33 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2004; (1) CD000206
34 Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2000; (2) CD000204
35 Soares-Weiser K V, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2003; (2) CD000208
36 Tammenmaa I A, McGrath J J, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2002; (3) CD000207
37 Tammenmaa I A, Sailas E, McGrath J J, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28 1099-1107
38 Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Higgins JPT, Green S In: The Cochrane Library. Chichester, UK; John Wiley & Sons, Ltd
39 Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 1539-1558
40 Egger M, Davey-Smith G, Altman D G. Systematic reviews in health care: meta-analysis in context. London; BMJ Publishing Group 2001: 487
41 Nordic Dyskinesia Study Group . Effect of different neuroleptics in tardive dyskinesia and parkinsonism: a video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology (Berl). 1986; 90 423-429
42 Double D B, Warren G C, Evans M, Rowlands R P. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand. 1993; 88 381-384
43 Elie R, Morin L, Tetreault L. Effets de l'ethopropazine et du trihexyphenidyle sur quelques parametres du syndrome neuroleptique. Encephale. 1972; 61 32-52
44 Friis T, Christensen T R, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983; 67 178-187
45 Gardos G, Cole J O, Rapkin R M et al.. Anticholinergic challenge and neuroleptic withdrawal: changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984; 41 1030-1035
46 Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl). 1978; 59 105-112
47 Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br J Psychiatry. 1984; 145 304-310
48 Klett C J, Caffey Jr E J. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry. 1972; 26 374-379
49 Csernansky J G, Tacke U, Rusen D, Hollister L E. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol. 1988; 8 154-155
50 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983; 17 523-527
51 Kojima T, Yamauchi T, Miyasaka M et al.. Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res. 1992; 43 129-136
52 Matsunaga T, Ohyama S, Takehara S et al.. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12 533-539
53 Buruma O J, Roos R A, Bruyn G W, Kemp B, van-der-Velde E. Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand. 1982; 65 38-44
54 Hebenstreit G F, Hoffmann H, Hoffmann W, Pittner H. [beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics]. Wien Klin Wochenschr. 1986; 98 388-392
55 Beckham B. Lecithin Therapy for Tardive Dyskinesia [dissertation]. Denton; North Texas State University 1981
56 Bockenheimer S, Lucius G. [Deanol in tardive dyskinesia: a double-blind study (author's transl)]. Arch Psychiatr Nervenkr. 1976; 222 69-75
57 de Montigny C, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl). 1979; 65 219-223
58 Gelenberg A J, Dorer D J, Wojcik J D, Falk W E, Brotman A W, Leahy L. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry. 1990; 51 149-153
59 George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry. 1981; 15 68-71
60 Jackson I. Cholinergic enhancement in tardive dyskinesia. Current Therapeutic Research. 1978; 24 725-733
61 Jackson I V, Nuttall E A, Ibe I O, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry. 1979; 136 1458-1460
62 Kocher R, Hobi V, Linder M, Studer K. [Treatment with dimethylaminoathanol (deanol) in neuroleptic induced tardive dyskinesia]. Schweiz Arch Neurol Neurochir Psychiatr. 1980; 126 103-109
63 Price L. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation [Ph.D. dissertation]. Denton; North Texas State University 1982: 147
64 Tarsy D, Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch Neurol. 1977; 34 756-758
65 Yagi G, Kamijima K, Miura S. Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia: a double-blind placebo-controlled study. Rinsho Hyoka. 1990; 18 455-479
66 Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia. Curr Ther Res Clin Exp. 1987; 42 111-114
67 Burner M, Giroux C, Lheritier C, Garreau M, Morselli P. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction. 1989; 2 289-296
68 Fisk G G, York S M. The effect of sodium valproate on tardive dyskinesia-revisited. Br J Psychiatry. 1987; 150 542-546
69 Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl). 1978; 56 145-151
70 Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry. 1976; 129 114-119
71 Nair N P, Yassa R, Ruiz-Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry. 1978; 135 1562-1563
72 Stewart R M, Rollins J, Beckam B. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin Neuropharmacol. 1982; 5 365-373
73 Thaker G K, Tamminga C A, Alphs L D, Lafferman J, Ferraro T N, Hare T A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia: reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry. 1987; 44 522-529
74 Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry. 1986; 143 912-914
75 Mouret J, Khomais M, Lemoine P, Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?. Eur Neurol. 1991; 31 199-203
76 Mackay A V, Sheppard G P, Saha B K, Motley B, Johnson A L, Marsden C D. Failure of lithium treatment in established tardive dyskinesia. Psychol Med. 1980; 10 583-587
77 Cookson I B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int Clin Psychopharmacol. 1987; 2 141-149
78 Kane J M, Rifkin A, Woerner M et al.. Low-dose neuroleptic treatment of outpatient schizophrenics. I: preliminary results for relapse rates. Arch Gen Psychiatry. 1983; 40 893-896
79 Emsley R, Turner H J, Schronen J, Botha K, Smit R, Oosthuizen P P. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004; 65 696-701
80 Glazer W M, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res. 1990; 3 315-320
81 Kazamatsuri H, Chien C, Cole J. Treatment of tardive dyskinesia. II: short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972; 27 100-103
82 Glazer W M, Naftolin F, Morgenstern H, Barnea E R, MacLusky N J, Brenner L M. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology. 1985; 10 345-350
83 Mosnik D M, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology. 1997; 16 136-146
84 Adler L A, Peselow E, Rotrosen J et al.. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993; 150 1405-1407
85 Adler L A, Rotrosen J, Edson R et al.. Vitamin E in the treatment of tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999; 56 836-841
86 Akhtar S, Jajor T, Kumar S. Vitamin E in the treatment of tardive dyskinesia. J Postgrad Med. 1993; 39 124-126
87 Dabiri L M, Pasta D, Darby J K, Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry. 1994; 151 925-926
88 Egan M F, Hyde T M, Albers G W et al.. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry. 1992; 149 773-777
89 Elkashef A M, Ruskin P E, Bacher N, Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am J Psychiatry. 1990; 147 505-506
90 Lam L C, Chiu H F, Hung S F. Vitamin E in the treatment of tardive dyskinesia: a replication study. J Nerv Ment Dis. 1994; 182 113-114
91 Lohr J B, Caligiuri M P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996; 57 167-173
92 Sajjad S H. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol. 1998; 13 147-155
93 Schmidt M, Meister P, Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur Psychiatry. 1991; 6 201-207
94 Soares K V, McGrath J J. The treatment of tardive dyskinesia: a systematic review and meta-analysis. Schizophr Res. 1999; 39 1-16 discussion 17-18
95 Weber S S, Dufresne R L, Becker R E, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983; 17 523-527

Hubert H FernandezM.D.

Program Director, Neurology Residency Training Program, University of Florida/McKnight Brain Institute

PO Box 100236, Gainesville, FL 32610